Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International journal of clinical practice

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1742-1241.2009.02002.xPMID 19187170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

  2009cited by this paper
• Translating the A1C Assay Into Estimated Average Glucose Values

  2008cited by this paper
• The Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of Biphasic Insulin Aspart: A Randomized, Glucose Clamp, Crossover Study

  2008cited by this paper
• When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study

  2008cited by this paper
• Guideline for management of postmeal glucose.

  2008cited by this paper
• Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

  2008cited by this paper
• The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts

  2008cited by this paper
• Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study

  2008cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008 The recommendations in this article are based on the evidence reviewed in the following publication: Standards of care for diabetes (Technical Review). Diabetes Care 17:1514–1522, 1994. Originally approved 1988. Most recent review/revision, October 2007.

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008

  2008cited by this paper
• Diabetes Care: Moving (a Little) in the Winds of Change

  2008cited by this paper
• Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

  2007cited by this paper
• Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

  2007cited by this paper
• Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

  2007cited by this paper
• Importance of observational studies in clinical practice.

  2007cited by this paper
• Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes

  2007cited by this paper
• Importance of observational studies in clinical practice.

  2007cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• Insulin regimens for type 2 diabetes mellitus

  2006cited by this paper
• Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes

  2006cited by this paper
• Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.

  2006cited by this paper
• Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

  2005cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Insulin therapy in type 2 diabetes.

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

  1997cited by this paper

• Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal–bolus insulin in UK clinical practice

  2023cites this paper
• COMPLICATIONS IN DIABETES : A REVIEW

  2022cites this paper
• Variation in hypoglycemia ascertainment and report in type 2 diabetes observational studies: a meta-epidemiological study

  2021cites this paper
• Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus

  2021cites this paper
• Glycemic improvement with a novel interim intervention technique using retrospective professional continuous glucose monitoring (GLITTER study): A study from Mumbai, India.

  2021cites this paper
• Interchangeabilité et substitution des biosimilaires

  2020cites this paper
• Capacity and confidence building for general practitioners on optimum insulin use

  2019cites this paper
• INSULINAS UTILIZADOS NO CONTROLE DA GLICEMIA EM PACIENTES COM DIABETES MELLITUS TIPO 1

  2019cites this paper
• Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment : Expert Panel Recommendations Tip 2

  2018cites this paper
• Regulation of biosimilar medicines and current perspectives on interchangeability and policy

  2018cites this paper
• CONCENTRATED INSULINS: CLINICAL APPLICATIONS & USE IN PRACTICAL SETTINGS.

  2017cites this paper
• Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management.

  2017cites this paper
• Interchangeability of Biosimilars: A European Perspective

  2017cites this paper
• Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes

  2017cites this paper
• 1 Switches between Comparable Products : Pharmacokinetics and Pharmacodynamics

  2017cites this paper
• on Diabetes Mellitus : Complications , Management and Treatment Modalities

  2016cites this paper
• Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature

  2016cites this paper
• Safety and effectiveness of insulin therapy in Chinese patients with type 2 diabetes mellitus : findings from the real-world SEAS study

  2016cites this paper
• Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis

  2015cites this paper
• An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

  2015cites this paper
• An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes

  2015cites this paper
• Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.

  2015cites this paper
• A Review on Diabetes Mellitus: Complications, Management and Treatment Modalities

  2015cites this paper
• Original article An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes

  2015cites this paper
• Risk of severe hypoglycaemia for various treatment regimens – a systematic review and meta-analysis of observational studies

  2014cites this paper
• Consensus evidence-based guidelines for insulin initiation, optimization and continuation in type 2 diabetes mellitus.

  2014cites this paper
• Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study

  2014cites this paper
• A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus – a systematic review and meta‐analysis

  2014cites this paper
• Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study

  2014cites this paper
• Clinical experience with BIAsp 30: Results from the Bangladesh cohort of the global A1chieve study.

  2014cites this paper
• Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A1 chieve study

  2014cites this paper
• A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.

  2014cites this paper
• Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen

  2013cites this paper
• Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

  2013cites this paper
• Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study.

  2013cites this paper
• Why is premixed insulin the preferred insulin? Novel answers to a decade-old question.

  2013cites this paper
• Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A1chieve)

  2013cites this paper
• Current drugs for the treatment of dry cough.

  2013cites this paper
• Predictors of postprandial blood glucose response to biphasic insulin analogue therapy.

  2013cites this paper
• Initiation of insulin aspart to Indian subjects on OADs show significant improvement in glycaemic outcomes: the A1chieve observational study.

  2013cites this paper
• Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the A₁chieve observational study.

  2013cites this paper
• Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.

  2013cites this paper
• Factors associated with a rapid normalization of HbA1c in newly diagnosed type 2 diabetes patients seen in a specialist setting

  2013cites this paper
• The A1chieve study – an observational non‐interventional study of patients with type 2 diabetes mellitus initiating or switched to insulin analogue therapy: subgroup analysis of the Gulf population

  2013cites this paper
• Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.

  2013influential citation
• Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes : Results from theASEAN cohort of the A 1 chieve study

  2013cites this paper
• Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes : a sub-analysis of the A 1 chieve study

  2013cites this paper
• Sécurité et efficacité de l’insuline détémir en initiation chez les patients algériens diabétiques de type 2: Résultats de l’étude A1chieve

  2013cites this paper
• Ten years of NovoMix 30 in Russian and international clinical practice

  2013cites this paper
• Biphasic insulin aspart 30: a guide to its use in diabetes mellitus

  2013cites this paper
• Safety and effectiveness of BIAsp 30 treatment: Data from the Moroccan cohort of the A 1 chieve study

  2013cites this paper
• Primordial prevention: maternal health and diabetes

  2013cites this paper
• Десять лет применения в мире и в России инсулина НовоМикс 30

  2013cites this paper
• Biphasic insulin aspart 30: a guide to its use in diabetes mellitus

  2013cites this paper
• Biopharmaceuticals as Challenges to the Regulatory System

  2012cites this paper
• Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naïve Patients with Type 2 Diabetes

  2012influential citation
• Baseline characteristics of the IMPROVE control study population: A study to evaluate the effectiveness of a standardized healthcare professionals training program

  2012cites this paper
• Gestational diabetes: the public health relevance and approach.

  2012cites this paper
• The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus

  2012cites this paper
• [Type 2 diabetes in the elderly, which specific features?].

  2012cites this paper
• Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence

  2012cites this paper
• Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

  2012cites this paper
• The safety of switching between therapeutic proteins

  2012cites this paper
• Ten Years of Experience with Biphasic Insulin Aspart 30

  2012cites this paper
• 2 Gestational Diabetes Mellitus-A Perspective

  2012cites this paper
• Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.

  2012influential citation
• Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs

  2012cites this paper
• Dwufazowe mieszanki insuliny i analogów insuliny u chorych na cukrzycę typu 2

  2012cites this paper
• Diagnosis of gestational diabetes mellitus in the community.

  2012cites this paper
• Diabète de type 2 chez le sujet âgé : quelles spécificités ?

  2012cites this paper
• Evolution of Insulin Development: Focus on Key Parameters

  2012cites this paper
• Insulin analogues: how observational studies provide key insights into management of patients with type 2 diabetes mellitus

  2011cites this paper
• Gestational Diabetes Mellitus - A Perspective

  2011cites this paper
• Evidence-based Synthesis Program

  2011cites this paper
• 二相性インスリンアナログ製剤（30Mix）と昼食直前α-グルコシダーゼ阻害薬併用の有用性の検討

  2011cites this paper
• Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long‐term modern premixed insulins in type 2 diabetes

  2011cites this paper
• Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes

  2011cites this paper
• Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes

  2010cites this paper
• A commentary on the “consensus statement” regarding the use of BIAsp30

  2010cites this paper
• The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.

  2010influential citation
• Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting

  2010cites this paper
• Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting

  2010cites this paper
• The safety and efficacy of biphasic insulin aspart 30 ( BIAsp 30 ) in Iranians with type 2 diabetes : an open-label , non-randomised , multi-centre observational study — the Iran subgroup of the IMPROVE TM study

  2010cites this paper
• 2型糖尿病患者における二相性インスリン アスパルト70（BIAsp 70）1日3回投与と二相性インスリン アスパルト30（BIAsp 30）1日2回投与時の24時間インスリンプロファイル―健康成人の生理的インスリンプロファイルとの比較―

  2010cites this paper
• Are Analogue Insulins Superior to Human Insulin in Clinical Practice?

  2010cites this paper
• Initiation of Biphasic Insulin Aspart in a Patient Failing Basal Insulin Treatment

  2010cites this paper
• Biphasic Insulin Aspart 30 in Insulin Initiation

  2010cites this paper
• Safety and efficacy of switching to biphasic insulin aspart 30/70 (BIAsp 30) under the routine diabetic care in patients with type 2 diabetes: The IMPROVE™ observational study in the Gulf region

  2010cites this paper
• IMPROVE™ observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus

  2010cites this paper
• Biphasic insulin aspart 30/70 (BiAsp 30) in the treatment of type 1 and type 2 diabetes

  2009cites this paper
• Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study

  2009cites this paper
• Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

  2009cites this paper
• Biphasic insulin aspart in the treatment of type 2 diabetes mellitus

  2009cites this paper
• Gestione del paziente anziano con diabete mellito Tipo 2: esperienza dallo studio osservazionale IMPROVE™ italiano Management of elderly patients with Type 2 diabetes mellitus: experience from the IMPROVE™ Italian observational study

  2009cites this paper
• [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart].

  2009cites this paper
• Step-up therapy with biphasic insulin aspart-70/30--Sapporo 1-2-3 study.

  2009cites this paper
• 2-es típusú cukorbetegek szénhidrát-anyagcseréjének, cardiovascularis és alkati paramétereinek változása bifázisos humán inzulinról analóg premix inzulinra történt terápiaváltás után

  2009cites this paper
• Biphasic Insulin Analogs for Treatment of Diabetes: A Review

  2009cites this paper
• Examining and interpreting responsiveness of the Diabetes Medication Satisfaction measure

  2009cites this paper